4
Changes in Ownership
TEVA PHARMACEUTICAL INDUSTRIES LTD Filed Acc 0001209191-20-020163
Executive VP, Global R&D sold 514 shares at $7.16 ($3,682)
- Executive VP, Global R&D acquired 1,014 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Fridriksdottir Hafrun · Executive VP, Global R&D
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2020-03-17 | Exercise or conversion : show line 1 in the form | +748 | 45,808.51 | D | ||
| 2020-03-17 | Exercise or conversion : show line 2 in the form | +266 | 46,074.51 | D | ||
| 2020-03-17 | Sale : show line 3 in the form | −380 | $7.16 | $2,722 | 45,694.51 | D |
| 2020-03-17 | Sale : show line 4 in the form | −134 | $7.16 | $960 | 45,560.51 | D |
| Open-market sales · 514 sh · avg $7.16 · $3,682 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2020-03-17 | Exercise or conversion : show line 5 in the form Restricted Share Units | −748 | 0 | D |
| 2020-03-17 | Exercise or conversion : show line 6 in the form Restricted Share Units | −266 | 0 | D |
Loading xslF345X03/doc4.xml…